Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Vinblastine [INN:BAN]
RN: 865-21-4
UNII: 5V9KLZ54CY
InChIKey: JXLYSJRDGCGARV-CFWMRBGOSA-N

Note

  • Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)

Molecular Formula

  • C46-H58-N4-O9

Molecular Weight

  • 810.9832
 

Classification Codes

  • Antimitotic Agents
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Drug / Therapeutic Agent
  • Human Data
  • Mitosis Modulators
  • Mutation Data
  • Natural Product
  • Reproductive Effect
  • Tubulin Modulators
  • Tumor Data

Names and Synonyms

Name of Substance

  • Vinblastine
  • Vinblastine [INN:BAN]

MeSH Heading

  • Vinblastine

Synonyms

  • (3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
  • 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid, 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-, methyl ester, (3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-
  • 29060-LE
  • CCRIS 9002
  • EINECS 212-734-0
  • HSDB 3263
  • NCI-C04842
  • NDC 0002-1452-01
  • Nincaluicolflastine
  • NSC 47842
  • NSC 49842
  • Rozevin
  • UNII-5V9KLZ54CY
  • Vinblastin
  • Vinblastina
  • Vinblastina [DCIT]
  • Vinblastine
  • Vinblastinum
  • Vinblastinum [INN-Latin]
  • Vincaleucoblastin
  • Vincaleucoblastine
  • Vincaleukoblastine
  • Vincoblastine
  • VLB
  • VR-8

Systematic Names

  • Vinblastine
  • Vincaleukoblastine

Registry Numbers

CAS Registry Number

  • 865-21-4

FDA UNII

  • 5V9KLZ54CY

System Generated Number

  • 0000865214

Structure Descriptors

InChI

InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1

InChIKey

JXLYSJRDGCGARV-CFWMRBGOSA-N

Smiles

CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C)[C@H]7[C@](O)([C@H](OC(=O)C)[C@]8(CC)C=CCN9CC[C@]67[C@H]89)C(=O)OC)C1

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
human TDLo ocular 14ug/kg (0.014mg/kg) SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE

SENSE ORGANS AND SPECIAL SENSES: CONJUNCTIVE IRRITATION: EYE

SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE		 British Journal of Ophthalmology. Vol. 62, Pg. 97, 1978.
man LDLo intravenous 2319ug/kg/38W (2.319mg/kg) CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION Lancet. Vol. 2, Pg. 692, 1980.
man TDLo unreported 80ug/kg (0.08mg/kg) BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE Cancer Chemotherapy Reports. Vol. 50, Pg. 219, 1966.
mouse LD10 subcutaneous 20mg/kg (20mg/kg)   European Journal of Cancer. Vol. 10, Pg. 667, 1974.
mouse LD50 intraperitoneal 3120ug/kg (3.12mg/kg) BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE

IMMUNOLOGICAL INCLUDING ALLERGIC: DECREASED IMMUNE RESPONSE		 Cancer Treatment Reports. Vol. 61, Pg. 103, 1977.
mouse LD50 intravenous 15mg/kg (15mg/kg)   United States Patent Document. Vol. #4279915,
rat LD50 intravenous 2mg/kg (2mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1467, 1970.

Physical Properties

Physical Property Value Units Temp (deg C) Source
log P (octanol-water) 3.7 (none)   EXP
Atmospheric OH Rate Constant 6.44E-10 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.